Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?

TrAC - Trends in Analytical Chemistry

Volumn 84, Issue , 2016, Pages 41-50

  Douxfils, Jonathan ^a   Pochet, Lionel ^a   Lessire, Sarah ^b   Vancraeynest, Christelle ^a   Dogné, Jean Michel ^a   Mullier, François ^b  

^a University of Namur   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Apixaban; Chromogenic assay; Coagulation tests; Dabigatran; Direct oral anticoagulants; Edoxaban; LC MS MS; Rivaroxaban

Indexed keywords

ASSAYS; COAGULATION; MASS SPECTROMETRY; PATIENT MONITORING; SPECTROMETRY;

APIXABAN; COAGULATION TESTS; DABIGATRAN; DIRECT ORAL ANTICOAGULANTS; EDOXABAN; LC-MS/MS; RIVAROXABAN;

DRUG PRODUCTS;

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; DIRECT ORAL ANTICOAGULANT; EDOXABAN; RIVAROXABAN; UNCLASSIFIED DRUG; VIPER VENOM;

BLOOD CLOTTING TEST; CHROMOGENIC ANTI XA ASSAY; CLINICAL PRACTICE; DILUTE RUSSELL VIPER VENOM TIME; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG RESPONSE; EVIDENCE BASED PRACTICE; GOLD STANDARD; HEMATOLOGY TEST KIT; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT ACCURACY; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; THROMBIN TIME; THROMBOEMBOLISM;

EID: 84961282384     PISSN: 01659936     EISSN: 18793142     Source Type: Journal    
DOI: 10.1016/j.trac.2016.01.029     Document Type: Review

References (93)

1. [1] Bloemen, S., De Laat, M., De Laat, B., Hemker, H.C., Al Dieri, R., Will one size of anticoagulant dosage fit all?. Drug Dev. Res 74 (2013), 406–412.
2. [2] Ten Cate, H., New oral anticoagulants: discussion on monitoring and adherence should start now!. Thromb. J., 11, 2013, 8.
3. [3] Douxfils, J., Mullier, F., Dogne, J.M., Dose tailoring of dabigatran etexilate: obvious or excessive?. Expert Opin. Drug Saf 14 (2015), 1283–1289.
4. [4] European Medicines Agency, Xarelto – Summary of Product Characteristics. 17/07/, 2015.
5. [5] European Medicines Agency, Pradaxa – Summary of Product Characteristics. 29/02/, 2016.
6. [6] European Medicines Agency, Eliquis – Summary of Product Characteristics. 12/02/, 2016.
7. [7] European Medicines Agency, Lixiana – Summary of Product Characteristics. 18/11/, 2015.
8. [8] Food and Drug Administration, Pradaxa – Prescribing Information. 20/11/, 2015.
9. [9] Food and Drug Administration, Xarelto – Prescribing Information. 10/09/, 2015.
10. [10] Food and Drug Administration, Eliquis – Prescribing Information. 10/09/, 2015.
11. [11] Food and Drug Administration, Savaysa – Prescribing Information. 10/09/, 2015.
12. [12] Nutescu, E., Chuatrisorn, I., Hellenbart, E., Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J. Thromb. Thrombolysis 31 (2011), 326–343.
13. [13] Liesenfeld, K.H., Lehr, T., Dansirikul, C., Reilly, P.A., Connolly, S.J., Ezekowitz, M.D., et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J. Thromb. Haemost 9 (2011), 2168–2175.
14. [14] Leil, T.A., Frost, C., Wang, X., Pfister, M., LaCreta, F., Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacometrics Syst. Pharmacol, 3, 2014, e136.
15. [15] Mueck, W., Stampfuss, J., Kubitza, D., Becka, M., Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin. Pharmacokinet 53 (2014), 1–16.
16. [16] Mismetti, P., Laporte, S., New oral antithrombotics: a need for laboratory monitoring. For. J. Thromb. Haemost 8 (2010), 621–626.
17. [17] Ten Cate, H., Monitoring new oral anticoagulants, managing thrombosis, or both?. Thromb. Haemost 107 (2012), 803–805.
18. [18] Food and Drug Administration, Xarelto – Clinical Pharmacology and Biopharmaceutics Review(s). 04/11/, 2011.
19. [19] Food and Drug Administration, Eliquis – Clinical Pharmacology and Biopharmaceutics Review(s). 28/12/, 2012.
20. [20] Pare, G., Eriksson, N., Lehr, T., Connolly, S., Eikelboom, J., Ezekowitz, M.D., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127 (2013), 1404–1412.
21. [21] Reilly, P.A., Lehr, T., Haertter, S., Connolly, S.J., Yusuf, S., Eikelboom, J.W., et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J. Am. Coll. Cardiol 63 (2014), 321–328.
22. [22] Ruff, C.T., Giugliano, R.P., Braunwald, E., Morrow, D.A., Murphy, S.A., Kuder, J.F., et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385 (2015), 2288–2295.
23. [23] Weitz, J.I., Connolly, S.J., Patel, I., Salazar, D., Rohatagi, S., Mendell, J., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb. Haemost 104 (2010), 633–641.
24. [24] Vogeser, M., Seger, C., A decade of HPLC-MS/MS in the routine clinical laboratory – goals for further developments. Clin. Biochem 41 (2008), 649–662.
25. [25] Adaway, J.E., Keevil, B.G., Therapeutic drug monitoring and LC-MS/MS. J. Chromatogr. B. Analyt Technol Biomed Life Sci 883–884 (2012), 33–49.
26. [26] Kubitza, D., Becka, M., Wensing, G., Voith, B., Zuehlsdorf, M., Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol 61 (2005), 873–880.
27. [27] Stangier, J., Rathgen, K., Stahle, H., Gansser, D., Roth, W., The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol 64 (2007), 292–303.
28. [28] Rohde, G., Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt Technol Biomed Life Sci 872 (2008), 43–50.
29. [29] Barrett, Y.C., Wang, J., Song, Y., Pursley, J., Wastall, P., Wright, R., et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb. Haemost 107 (2012), 916–924.
30. [30] Bathala, M.S., Masumoto, H., Oguma, T., He, L., Lowrie, C., Mendell, J., Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab. Dispos 40 (2012), 2250–2255.
31. [31] Schmitz, E.M., Boonen, K., van den Heuvel, D.J., van Dongen, J.L., Schellings, M.W., Emmen, J.M., et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography – tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J. Thromb. Haemost 12 (2014), 1636–1646.
32. [32] Delavenne, X., Mismetti, P., Basset, T., Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J. Pharm. Biomed. Anal 78–79 (2013), 150–153.
33. [33] Douxfils, J., Dogne, J.M., Mullier, F., Chatelain, B., Ronquist-Nii, Y., Malmstrom, R.E., et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb. Haemost 110 (2013), 543–549.
34. [34] Douxfils, J., Tamigniau, A., Chatelain, B., Chatelain, C., Wallemacq, P., Dogne, J.M., et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb. Haemost 110 (2013), 723–731.
35. [35] Antovic, J.P., Skeppholm, M., Eintrei, J., Boija, E.E., Soderblom, L., Norberg, E.M., et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur. J. Clin. Pharmacol 69 (2013), 1875–1881.
36. [36] Skeppholm, M., Hjemdahl, P., Antovic, J.P., Muhrbeck, J., Eintrei, J., Ronquist-Nii, Y., et al. On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation. Thromb. Res 134 (2014), 783–789.
37. [37] Skeppholm, M., Al-Aieshy, F., Berndtsson, M., Al-Khalili, F., Ronquist-Nii, Y., Soderblom, L., et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb. Res 136 (2015), 148–153.
38. [38] Vogeser, M., Seger, C., Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin. Chem 56 (2010), 1234–1244.
39. [39] Clarke, W., Rhea, J.M., Molinaro, R., Challenges in implementing clinical liquid chromatography-tandem mass spectrometry methods – the light at the end of the tunnel. J. Mass Spectrom 48 (2013), 755–767.
40. [40] Annesley, T., Majzoub, J., Hsing, A., Wu, A., Rockwood, A., Mason, D., Mass spectrometry in the clinical laboratory: how have we done, and where do we need to be?. Clin. Chem 55 (2009), 1236–1239.
41. [41] Douxfils, J., Tamigniau, A., Chatelain, B., Goffinet, C., Dogne, J.M., Mullier, F., Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb. J., 12, 2014, 24.
42. [42] Douxfils, J., Mani, H., Minet, V., Devalet, B., Chatelain, B., Dogne, J.M., et al. Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations. Biomed Res. Int, 2014, 2014 345138.
43. [43] van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K.H., Wienen, W., Feuring, M., et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost 103 (2010), 1116–1127.
44. [44] Douxfils, J., Mullier, F., Robert, S., Chatelain, C., Chatelain, B., Dogne, J.M., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb. Haemost 107 (2012), 985–997.
45. [45] Pernod, G., Albaladejo, P., Godier, A., Samama, C.M., Susen, S., Gruel, Y., et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) – March 2013. Arch. Cardiovasc. Dis 106 (2013), 382–393.
46. [46] Lessire, S., Douxfils, J., Baudar, J., Bailly, N., Dincq, A.S., Gourdin, M., et al. Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thromb. Res 136 (2015), 693–696.
47. [47] Gosselin, R., Hawes, E., Moll, S., Adcock, D., Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels. Am. J. Clin. Pathol 141 (2014), 262–267.
48. [48] Schmohl, M., Gansser, D., Moschetti, V., Stangier, J., Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis. Thromb. Res 135 (2015), 532–536.
49. [49] Hawes, E.M., Deal, A.M., Funk-Adcock, D., Gosselin, R., Jeanneret, C., Cook, A.M., et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J. Thromb. Haemost 11 (2013), 1493–1502.
50. [50] Helin, T.A., Lemponen, M., Hjemdahl, P., Ronquist-Nii, Y., Lassila, R., Joutsi-Korhonen, L., From laboratory to clinical practice: dabigatran effects on thrombin generation and coagulation in patient samples. Thromb. Res 136 (2015), 154–160.
51. [51] Gosselin, R.C., Adcock, D., Hawes, E.M., Francart, S.J., Grant, R.P., Moll, S., Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb. Haemost 113 (2015), 77–84.
52. [52] Douxfils, J., Lessire, S., Dincq, A.S., Hjemdahl, P., Ronquist-Nii, Y., Pohanka, A., et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb. Haemost 113 (2015), 862–869.
53. [53] Bozic-Mijovski, M., Malmstrom, R.E., Malovrh, P., Antovic, J.P., Vene, N., Sinigoj, P., et al. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations. Ann. Clin. Biochem, 2015, 10.1177/0004563215599795.
54. [54] Samos, M., Stanciakova, L., Ivankova, J., Stasko, J., Kovar, F., Dobrotova, M., et al. Monitoring of dabigatran therapy using Hemoclot((R)) Thrombin Inhibitor assay in patients with atrial fibrillation. J. Thromb. Thrombolysis 39 (2015), 95–100.
55. [55] Gosselin, R.C., Dwyre, D.M., Dager, W.E., Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann. Pharmacother 47 (2013), 1635–1640.
56. [56] Dager, W.E., Gosselin, R.C., Kitchen, S., Dwyre, D., Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann. Pharmacother 46 (2012), 1627–1636.
57. [57] Lindahl, T.L., Baghaei, F., Blixter, I.F., Gustafsson, K.M., Stigendal, L., Sten-Linder, M., et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb. Haemost 105 (2011), 371–378.
58. [58] Harenberg, J., Giese, C., Marx, S., Kramer, R., Determination of dabigatran in human plasma samples. Semin. Thromb. Hemost 38 (2012), 16–22.
59. [59] Van Blerk, M., Bailleul, E., Chatelain, B., Demulder, A., Devreese, K., Douxfils, J., et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb. Haemost 113 (2015), 154–164.
60. [60] He, S., Wallen, H., Bark, N., Blomback, M., In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J. Thromb. Thrombolysis 35 (2013), 131–139.
61. [61] Baglin, T., Keeling, D., Kitchen, S., British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br. J. Haematol 159 (2012), 427–429.
62. [62] Baglin, T., Hillarp, A., Tripodi, A., Elalamy, I., Buller, H., Ageno, W., Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost 11 (2013), 756–760.
63. [63] Kim, Y.A., Gosselin, R., Van Cott, E.M., The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int. J. Lab. Hematol 37 (2015), e81–e84.
64. [64] Nowak, G., The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol. Haemost. Thromb 33 (2003), 173–183.
65. [65] Mueck, W., Borris, L.C., Dahl, O.E., Haas, S., Huisman, M.V., Kakkar, A.K., et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb. Haemost 100 (2008), 453–461.
66. [66] Mueck, W., Eriksson, B.I., Bauer, K.A., Borris, L., Dahl, O.E., Fisher, W.D., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet 47 (2008), 203–216.
67. [67] Barrett, Y.C., Wang, Z., Frost, C., Shenker, A., Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb. Haemost 104 (2010), 1263–1271.
68. [68] Samama, M.M., Martinoli, J.L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., et al. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thromb. Haemost 103 (2010), 815–825.
69. [69] Hillarp, A., Baghaei, F., Fagerberg Blixter, I., Gustafsson, K.M., Stigendal, L., Sten-Linder, M., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J. Thromb. Haemost 9 (2011), 133–139.
70. [70] Douxfils, J., Mullier, F., Loosen, C., Chatelain, C., Chatelain, B., Dogne, J.M., Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb. Res 130 (2012), 956–966.
71. [71] Douxfils, J., Chatelain, B., Chatelain, C., Dogne, J.M., Mullier, F., Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide. Thromb. Haemost, 115, 2015.
72. [72] Becker, R.C., Alexander, J.H., Newby, L.K., Yang, H., Barrett, Y., Mohan, P., et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb. Haemost 104 (2010), 976–983.
73. [73] Douxfils, J., Chatelain, C., Chatelain, B., Dogne, J.M., Mullier, F., Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb. Haemost 110 (2013), 283–294.
74. [74] Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R.A., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br. J. Clin. Pharmacol 76 (2013), 776–786.
75. [75] Gouin-Thibault, I., Flaujac, C., Delavenne, X., Quenet, S., Horellou, M.H., Laporte, S., et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb. Haemost 111 (2014), 240–248.
76. [76] Francart, S.J., Hawes, E.M., Deal, A.M., Adcock, D.M., Gosselin, R., Jeanneret, C., et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb. Haemost 111 (2014), 1133–1140.
77. [77] Becker, R.C., Yang, H., Barrett, Y., Mohan, P., Wang, J., Wallentin, L., et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban – an oral, direct and selective factor Xa inhibitor. J. Thromb. Thrombolysis 32 (2011), 183–187.
78. [78] Douxfils, J., Chatelain, B., Hjemdahl, P., Devalet, B., Sennesael, A.L., Wallemacq, P., et al. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb. Res 135 (2015), 852–860.
79. [79] Gosselin, R.C., Adcock Funk, D.M., Taylor, J.M., Francart, S.J., Hawes, E.M., Friedman, K.D., et al. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch. Pathol. Lab. Med 138 (2014), 1680–1684.
80. [80] Hillarp, A., Gustafsson, K.M., Faxalv, L., Strandberg, K., Baghaei, F., Fagerberg Blixter, I., et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J. Thromb. Haemost 12 (2014), 1545–1553.
81. [81] Mani, H., Hesse, C., Stratmann, G., Lindhoff-Last, E., Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb. Haemost 109 (2013), 127–136.
82. [82] Lindhoff-Last, E., Samama, M.M., Ortel, T.L., Weitz, J.I., Spiro, T.E., Assays for measuring rivaroxaban: their suitability and limitations. Ther. Drug Monit 32 (2010), 673–679.
83. [83] Samama, M.M., Amiral, J., Guinet, C., Perzborn, E., Depasse, F., An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb. Haemost 104 (2010), 1078–1079.
84. [84] Samama, M.M., Contant, G., Spiro, T.E., Perzborn, E., Guinet, C., Gourmelin, Y., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb. Haemost 107 (2012), 379–387.
85. [85] Samama, M.M., Guinet, C., Le Flem, L., Ninin, E., Debue, J.M., Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J. Thromb. Thrombolysis 35 (2013), 140–146.
86. [86] Samama, M.M., Mendell, J., Guinet, C., Le Flem, L., Kunitada, S., In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb. Res 129 (2012), e77–e82.
87. [87] Mani, H., Rohde, G., Stratmann, G., Hesse, C., Herth, N., Schwers, S., et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb. Haemost 108 (2012), 191–198.
88. [88] Gosselin, R.C., Francart, S.J., Hawes, E.M., Moll, S., Dager, W.E., Adcock, D.M., Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level?. Ann. Pharmacother 49 (2015), 777–783.
89. [89] Exner, T., Ellwood, L., Rubie, J., Barancewicz, A., Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study. Thromb. Haemost 109 (2013), 762–765.
90. [90] Altman, R., Gonzalez, C.D., Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb. J., 12, 2014, 7.
91. [91] Altman, R., Gonzalez, C.D., Supporting the use of a coagulometric method for rivaroxaban control: a hypothesis-generating study to define the safety cut-offs. Thromb. J., 13, 2015, 26.
92. [92] McGlasson, D.L., Fritsma, G.A., Measuring dabigatran with the dilute Russell viper venom confirm assay in an anticoagulation clinic population. Blood Coagul. Fibrinolysis 27:1 (2015), 53–57, 10.1097/MBC.0000000000000382.
93. [93] Asmis, L.M., Alberio, L., Angelillo-Scherrer, A., Korte, W., Mendez, A., Reber, G., et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb. Res 129 (2012), 492–498.